Categories AlphaGraphs, Health Care
Infographic: Highlights from Gilead Sciences (GILD) Q2 2020 earnings
Gilead Sciences (NASDAQ: GILD) reported second-quarter financial results after the closing bell on Thursday. The biotechnology firm missed both the revenue and earnings estimates for the quarter.
GILD shares fell over 2% immediately following the announcement. The stock has gained 11% since the beginning of this year.
CEO Daniel O’Day said, “We are also making important progress with our pipeline. In addition to the critical work of advancing remdesivir, we have continued to strengthen our presence in immuno-oncology. This includes six immuno-oncology agreements this year and the recent FDA approval for TecartusTM in mantle cell lymphoma.”
Prior performance
[irp posts=”67604″]
____
Most Popular
Can General Motors (GM) navigate the tariff challenge ahead?
General Motors' (NYSE: GM) stock tumbled last week after the Trump administration imposed new tariffs on automobile imports, raising concerns about their potential impact on the company’s production as it
What to look for when Delta Air Lines (DAL) reports its Q1 2025 earnings results
Shares of Delta Air Lines (NYSE: DAL) were down over 1% on Monday. The stock has dropped 28% over the past three months. The airline is scheduled to report its
STZ Earnings Preview: Can Constellation Brands leverage growing beer sales?
Constellation Brands, Inc. (NYSE: STZ) has effectively navigated challenges like cautious consumer spending and declining demand for its wine and spirits brands by capitalizing on the sustained growth in the
